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Cover Letter 
 
Dear Dr Heal, 
 
Please find enclosed a manuscript as commissioned for the special edition of 
Neuropharmacology focussing on psychedelic drugs. I have extensively reworked the 
manuscript in line with the comments from the reviewers and the need to create a hybrid 
article between the two briefs that you originally discussed with David Nutt. Pursuant to 
this, I have updated the title but am quite content if you would like to modify this. Many 
thanks for the comments from you and the two reviewers, which I hope have shaped this 
into a piece of work more appropriate for the upcoming special issue. 
 
Yours sincerely, 
 
James Rucker 
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Response to Reviewers 
Reviewer #1: The topic of the review fits well within the remit of the Neuropharmacology 
Special Issue on Psychedelics. Although it will appear as a stand-alone article on-line, this 
article will be the final review in the printed version of the issue of the journal and its brief 
was to be thought provoking and challenging. The original brief was a review on the topic 
"Are psychedelics the future in psychiatric treatment?" A review exploring early clinical and 
preclinical research with the psychedelics and the events leading up to the introduction of 
highly restrictive legislation that almost killed off all work in the field is the subject of 
another invited review. This could result in a large degree of overlap and duplication. 
However, this section of the manuscript under evaluation makes interesting reading and the 
overlap issue can be addressed by some judicious editing and reformatting of the 
manuscript. 
 
1. The title is inappropriate for the brief and needs to be changed to something like "Future 
role of psychedelic drugs in psychiatry - a critical evaluation based on evidence from past 
and present trials." 
 
It is unfortunate, but it appears that both you and I have been misinformed about the 
brief. You were told that the brief was 'Are psychedelics the future in psychiatric 
treatment?’. I was told that the brief was 'Clinical studies with psychedelic drugs'. In fact, 
the editor and the last author had a discussion in which they decided to combine both 
briefs into a single project, however neither of them told me about this, and it only 
became apparent when I contacted the editor after reading your comments. I have 
interpreted much of your criticism in light of this and the article is now a hybrid between 
the two briefs, meaning that the concerns re: overlap are presumably superfluous. More 
specifically, and having discussed with both David Heal and David Nutt, the paper 
includes the following general restructuring 
1. Reduction in overall length to 10,000 words 
2. Removal of some study descriptions 
3. Reduction of 'tactical' discussion re: clinical trials 
4. Introduction of 'strategic' discussion in line with your points 
 
2. The review already contains a critique of the data from early trials and those up to the 
point when the psychedelics were bundled into Schedule 1. However, it comes too late in 
the manuscript. It needs to come before any description/discussion of current or future 
clinical research. Also, the evaluation of the field provided by the authors reads like it has 
been written by a "true believer". It needs to be much more critical, hard-nosed and 
objective because the regulatory hurdles facing the development of the psychedelics for 
approved medical use are enormous. 
 
I have modified the language, removed speculation and tried to be more objective. It 
is true that I believe that psychedelics deserve to be tested with modern paradigms 
of trial design, but I am too clinically long in the tooth to be a ‘true believer’ in 
anything when it comes to therapeutics in psychiatry! 
 
I have moved the discussion of pre-prohibition trials after the description of same. 
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3. The description of current best practise is far too long, detailed and tactical rather than 
strategic. It does not address how to break the Catch 22 situation that psychedelics will 
remain in C-I until they have an approved medical use, conducting large scale clinical trials 
with C-I drugs is a logistical nightmare and no-one will accept the challenge, and therefore, 
the psychedelics will remain in C-I. 
 
I have considerably shortened this, pursuant to my comments under (1) above. 
 
For the FDA or EMA to approve a psychedelic drug, it needs objective evidence of 
efficacy from randomised, double-blind, placebo-controlled trials and evidence of 
safety for up to 2 years. The alternative is the orphan drug route being pursued by 
Rowland Griffiths and his colleagues in terminal cancer associated anxiety and 
depression.  
 
Key questions that need to be addressed in the review are: 
(i) Orphan drug status or regular approval of the psychedelic in say treatment-resistant 
depression or alcohol dependence? 
 
Regular approval. Given the FDA definitions and requirements with regards to 
orphan drugs, I am unsure how this would work. I have added this to the review. 
 
(ii) Where will these patients come from and how many will need to be recruited? 
 
Most efficacy trials include several hundred patients and the phase 3 efficacy RCTs 
currently in preparation for psilocybin in treatment resistant depression aim to 
collect 300 patients in 6 different centres. Patients will be a mixture of self referrals, 
referrals from primary, secondary and tertiary care centres and via established 
clinical research registries and third sector organisations. I have added this to the 
review. 
 
(iii) What clinical centres will conduct this research? 
 
Those that, like ours, have the relevant legal approvals, appropriately qualified 
personnel and infrastructure to support trials with Schedule 1 drugs. Which other 
centres around the world have this expertise I could not necessarily say, but 
presumably those who have published trials in this area have a similar infrastructure 
to our own and successful dissemination will inspire others. I have added this to the 
review. 
 
(iv) Where will the safety database come from? Not an issue in terminal cancer 
depression. 
 
I have added a description of our current plans about this to the review.  
 
(v) Who will pay for the clinical studies? Psilocybin, mescaline, LSD etc are all generic 
drugs. 
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(vi) What about the industry involvement? Companies will only pay for development if 
there is a firm IP position. Thousands of analogues of phenylethylamines and tryptamines 
have been synthesised confounding the search for novel molecules. What motivator is there 
for developing a patent-protected novel 5-HT2A agonist, if the same job can be done a 
psilocybin or mescaline? 
 
Dealing with points (v) and (vi) leads to commercially sensitive information. We are 
therefore deliberately circumspect, although can confirm that despite its generic 
status, there is sufficient commercial potential for the development of psilocybin for 
it to attract the funding required for phase 3 trials. I have added this to the review. 
 
(vii) How do you conduct blinded placebo-controlled trials with drugs that have profound 
psychoactive effects? 
 
This is already discussed in the review. There is no easy answer to this question but it 
is not specific to psychedelics and we do not think that this limitation means that the 
research should not be done. Opinion is divided, so we discuss these. We think that 
active placebos combined with outcome raters blinded to treatment allocation is the 
most suitable combination of trial design elements to mitigate the problem with 
blinding. 
 
(viii) Do the authors believe that there will be prescriber and/or patient acceptance of the 
psychedelic drugs as treatments in psychiatry? 
 
I doubt we would be in the field at all if we didn’t. It will be a long hard road, but 
probably an interesting one! My psychiatric colleagues have greeted the research 
with reactions that vary from scepticism to enthusiasm with the majority being 
benignly agnostic. Ultimately, the evidence will speak for itself and it may tell us that 
the drugs are ineffective. 
 
The authors have a very good existing framework in the manuscript on which to build. 
However, as a key review in the Special Issue on Psychedelics, it requires substantial revision 
with more focus on the strategic topics described above and far less on tactical matter like 
whether to hold subject's hands while they are undergoing therapy. 
 
This is fine, although again I refer to my original point about the brief. There is 
relatively little in the published literature about the specific pragmatics of 
psychedelic trials, which do come with unique challenges that reflect the drug’s 
MoA. However, pursuant to my wider comments above, I have significantly revised 
and reduced the section covering this. 
 
Referencing errors 
All the references are in the manuscript and cited in Reference list. However, there are 
various errors in the manuscript that need to be addressed. 
 
In the Introduction, para 3, WHO needs the date in brackets. 
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 Done 
 
Section 1940-1970: Studies in psychotic disorders 
In para 2, Busch & W.C. Johnson, 1950 - the initials need to be removed. 
 
I believe that the referencing software (which is set to reference specifically for the 
style required for this journal) inserts initials to disambiguate surnames in cases 
where there are different authors with the same surname amongst the reference 
list. I have left it as it is, but presumably this will be cleared up in the pre-publishing 
process if it is an issue. 
 
Section 1940-1970: Studies in neurotic disorders 
In para 5, Eisner and S. Cohen, 1958 - the initial needs to be removed. 
 
As above 
 
Discussion 
In para 5, M.M. Cohen et al, 1967 - the initials need to be removed. 
 
As above. 
 
Returning (and re-tuning ) to psychedelic research 
In para 5, the reference to "World Health Organisation | Depression," n.d. needs the date 
adding. 
 
Done 
 
In para 7, S. Cohen, 1960 - the initial needs to be removed. 
 
As above 
 
In para 7, S. Cohen and Ditman, 1963 - the initial needs to be removed. 
 
As above 
 
In para 17, "Certificate in Psychedelic-Assisted Therapies and Research | CIIS," n.d. needs 
the date adding. 
 
Done 
 
Table 
Hoch needs et al to be added. 
 
 Done 
 
Maclean needs et al to be added. 
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 Done 
 
Whitaker needs to state a or b. 
 
 Done 
 
Smart needs et al to be added. 
 
 Done 
 
Savage needs et al to be added. 
 
 Done 
 
Hollister needs et al to be added. 
 
 Done 
 
Ludwig needs et al to be added. 
 
 Done 
 
Carhart-Harris et al, needs to state a or b. 
 
 Done 
 
 Many thanks for your comprehensive and insightful comments. 
 
Reviewer #2: This is a fascinating review, which I enjoyed reading.  I am not a science 
historian and so cannot comment on that aspect of this review. However, it is well-written, 
extremely interesting and the material has been assimilated in a sensible way (subject to 
comments, below).  There is no doubt that it will be highly cited.  Some comments and 
suggestions are: 
General 
1. My main comment is that it is rather long.  That is an editorial decision, of course, 
but I believe that some of the material can be condensed, or even excluded, without 
diluting the main messages of the article.  For instance, the descriptions of the clinical trials 
is tending towards a list, with each paragraph being a resume of a specific paper.  That said, 
each one includes a brief critique from the authors, which helped to maintain this reader's 
interest. 
 
This was also raised by reviewer 1 and the editor and arose in part because I was 
misinformed about the brief. I have updated the title, considerably shortened the 
manuscript and sharpened its focus 
 
2. Given that that material is extensive, Table 1 is really important.  However, again, as 
presented it is another list (a summary of the summaries).  It might be worth considering 
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dividing that material into three group:  studies that suggested efficacy;  those that did not; 
and outcome unclear.  That would help to amplify the authors' key point:  that there is 
enough evidence for efficacy to press for clinical trials.  At the moment, the justification for 
that claim is a bit blurred. 
 
I have reworked this table to include a column that indicates a binary judgement 
about the presence or absence of efficacy and two columns that indicate immediate 
and delayed adverse events reported in each of the trials. I have sorted the table by 
disease, then by year of publication, which makes it easier for the reader to compare 
efficacy in different disease states they might be interested in. 
 
3. This is a translational review and so the, somewhat cursory, attendance to 
underlying pharmacology (at the end of the article) feels out of place.  I would advise 
removing it.  If the authors decide not to do that, they need to revise that material to make 
it clear that the pharmacology of these drugs is more complicated than that and  that 
activation of  5-HT2A receptors seems to be a common factor but, alone, cannot explain the 
effects of any of them. (I expect that topic will be covered in other articles in this issue) 
 
I have removed this. 
 
4. The material dealing with the clinical trials also feels out of place.  The authors could 
say that they have given this much thought and mention key variables.  I do not think that 
the several pages of details fits with the scope of this journal. 
 
This element of the review has been considerably abridged and shortened. 
 
5. Harm and safety crop up at several points in the review.  I wonder whether this topic 
should be covered, in a separate section early on?  Many readers will want to know about 
that before they make their judgement on efficacy as they read through the descriptions of 
the trials.  In fact, a Table 2 could be helpful.  This could mirror Table 1, but deal in adverse 
effects instead?  
 
I have added this to table 1, as described. I have added reference to harms in the 
introduction and in the discussion sections. 
 
Minor:  
6. Abstract.  What is the difference between efficacy and effectiveness? 
 
I have added some indications about this. The basic difference is that for a drug to be 
effective it must be efficacious and also deliverable in real-world healthcare settings. 
 
7. Page 9: (In the section, 1895-1940. Studies with Mescaline)  - animals, and was 
limited. Should read were 
 
This paragraph has been removed pursuant to the need to shorten the manuscript. 
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8. Page 13, para 2:  States that - drugs were ineffective, and possibly harmful- 
.  Presumably this means harm in the sense of exacerbation of psychiatric symptoms?  I 
think this needs clarification because earlier it is stated that psychedelics cause no harm. 
 
I have clarified this. 
 
9. In the sections dealing with psychosis, especially schizophrenia, the lack of any 
mention of auditory hallucinations is striking.  A comment on that would be interesting 
 
It is, indeed, an interesting point that the psychedelics tend to produce visual 
misperceptions whilst schizophrenic syndromes tend to produce auditory 
misperceptions. This was pointed out in a pre-prohibition study that compared the 
phenomenology of healthy controls given LSD to patients with schizophrenia, but I 
have removed it from this review in the interests of space. However, I have made 
reference to it in the discussion. 
 
10. Page 17, para 2:  Here it is said that  - Patients were assessed for suitability,- .  It 
would be interesting to know what criteria were used to determine that. 
 
This study has been removed pursuant to the need to shorten the paper. 
 
11. Page 19, para 4:  what was 'standard care' (in those days)? 
 
This isn’t well defined and depended on the study but generally followed the 
principles of AA or simply regular consultations with a psychiatrist. 
 
12. Page 21 para 2.  Here it is states that there is evidence against dependence -.  I think 
I am correct in  saying that this is the first mention of dependence in the article?.   Given the 
importance of this risk (the regulatory authorities will want to know about this), I think a 
section discussing the evidence for and against should be included.  Perhaps a Table 3 on 
this too?  
 
I have added a paragraph on the risk of physiological dependence, psychological 
dependence, abuse and diversion. 
 
Many thanks for your comprehensive and insightful comments. 
 
GUEST EDITOR'S DECISION 
 
Dear Dr Rucker 
 
Thank-you for submitting the invited review entitled "Clinical Trials with Psychedelic Drugs. 
Past, Present & Future" to the Special Issue of Neuropharmacology on Psychedelics.  The 
manuscript has been reviewed by two referees who are familiar with the subject matter of 
your review and the scope and content of the Special Issue itself.  
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Both Reviewers have raised important points. The ones of most significance are the 
excessive length and detail in the review, the need for greater objectivity, and a focus on 
tactical issues while failing to address the difficult strategic challenges that face the 
development of psychedelics for medical use. The Referees' comments are very detailed to 
assist you and your co-authors to revise the manuscript. Professor Dave Nutt, one of the 
other Guest Editors on this Special issue, is a co-author on the manuscript. He is very 
knowledgeable on the strategic challenges facing the clinical development of the 
psychedelics. His input in providing the strategic input will be essential. The other concern 
that I have as a Guest Editor is the overlap of content in your review and that of another 
invited contribution. Reviewer 1 has suggested a compromise that should address the 
problem without putting too much extra work onto you and your co-authors. 
 
At this point my decision is "Major revision" so please carefully address the points raised by 
the Reviewers. We look forward to receiving the revised version of the manuscript. If 
possible, we would like you to submit your revised manuscript within the next 4 weeks. 
 
On behalf of the Guest Editors, we thank you for supporting the Special Issue of 
Neuropharmacology on Psychedelics. 
 
With kind regards 
 
David Heal 
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Abstract 
The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and 
mescaline, were used extensively in psychiatry before they were placed in Schedule I of the 
UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to 
legal sanction suggest that they are not helpful for those with established psychotic 
disorders and should be avoided in those liable to develop them. However, those with so-
called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to 
‘loosen’ otherwise fixed, maladaptive patterns of cognition and behaviour, particularly 
when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were 
sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-
analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events 
appears to be low. Since 2006, there have been several pilot trials and randomised 
controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric 
disorders. These have provided encouraging results that provide initial evidence of safety 
and efficacy, however the regulatory and legal hurdles to licensing psychedelics as 
medicines are formidable. This paper summarises clinical trials using psychedelics pre and 
post prohibition, discusses the methodological challenges of performing good quality trials 
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in this area and considers a strategic approach to the legal and regulatory barriers to 
licensing psychedelics as a treatment in mainstream psychiatry. 
Key Words 
Psychedelics 
Psychiatric disorders 
Clinical trials 
Introduction 
The classical psychedelic drugs include mescaline, psilocybin, dimethyltryptamine (DMT) 
and d-lysergic acid diethylamide (LSD). Coined by psychiatrist Humphrey Osmond in a letter 
he wrote to Aldous Huxley in 1956, the word ‘psychedelic’ is derived from the ancient Greek 
words psychē (ψυχή, translated as “soul” or “mind”) and dēloun (δηλοῦν, translated as “to 
reveal” or “to manifest”). Therefore, psychedelic literally translates as ‘mind manifesting’ or 
‘soul revealing’(Osmond, 1957). Other terms such as ‘hallucinogen’ and ‘psychotomimetic’ 
are less favoured, perhaps because they place too much emphasis on individual elements of 
a multi-faceted subjective state. 
 
Psychedelics were used long before the Western world was introduced to them in 1897, 
when Arthur Heffter isolated mescaline from the peyote cactus. The earliest direct evidence 
for use of psychotropic plants dates back 5,700 years in the north eastern region of 
Mexico(Bruhn et al., 2002), where carbon-dated buttons of peyote cacti and red beans 
containing mescaline were found in caves used for human habitation. The Eleusian 
ceremonies of ancient Greece were likely based around some form of psychedelic 
compound(Wasson et al., 2008). Psilocybin containing ‘magic’ mushrooms, which grow all 
over the world, appear to have been used ubiquitously(Akers et al., 1992; Letcher, 2008). 
Mescaline is still used in Native American Church ceremonies(O. C. Stewart, 1987). In 
Brazil(McKenna et al., 1984) and the broader Amazonian basin(Schultes and Hofmann, 
1979), ritual healing practices and spiritual ceremonies are practiced using ayahuasca, a 
drink which combines plant derived DMT and β-carboline monoamine oxidase inhibitors 
that allow it to be used orally.   
 
The archetypal psychedelic in modern Western society, LSD, was first synthesised in 1938 by 
Albert Hofmann as part of a systematic investigation of compounds derived from the ergot 
alkaloids at the Sandoz laboratories in Switzerland(Hofmann, 2013). The ergot alkaloids, 
which include lysergic acid and its derivatives, were known to be responsible for episodes of 
mass poisoning in medieval Europe from stocks of grain spoiled with the parasitic fungus 
Claviceps Purpurea. In smaller doses, a specific ergot alkaloid (ergometrine) was also known 
to be effective for treating bleeding in women after childbirth due to its vaso- and utero-
constrictive properties. LSD was the 25th derivative of lysergic acid that Hofmann 
synthesised, explaining why it is sometimes referred to as ‘LSD-25’(Hofmann, 2013). 
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In animal testing, LSD was found to be physiologically unremarkable and the compound was 
shelved. Hofmann describes how he decided to resynthesize LSD in 1943 on the basis of a 
‘peculiar presentiment…that this [compound] might possess properties beyond those 
established in the first pharmacological studies’(Hofmann, 2013). On April 16th of that year 
Hofmann accidentally contaminated himself with a small amount and, noticing some 
unusual psychic effects, purposefully ingested 250 micrograms 3 days later. The full, and 
remarkably potent, effects of LSD on the psyche became apparent for the first time. Further 
investigation of LSD by Sandoz found that, despite its potency, it was a notably safe 
compound physiologically. Recognising that its psychoactive properties were likely to be of 
interest both to psychiatrists and academics, it was marketed in 1947 under the trade name 
‘Delysid’ and made freely available to those interested in researching its properties. 
Hofmann also isolated and synthesised the active component of psilocybe ‘magic’ 
mushrooms, psilocybin, in 1958(Hofmann et al., 1959). This was marketed by Sandoz under 
the brand name ‘Indocybin’. 
 
At a time when psychiatry lacked effective medical therapies, the discovery of LSD was of 
interest, with some key features noted. Firstly, acute intoxication appeared to mimic some 
of the symptoms of acute psychosis, particularly ego-dissolution, thought disorder and 
visual misperceptions (although not, notably, auditory hallucinations). Secondly, there 
appeared to be an increased awareness of (and emotional connection to) repressed 
memories and other elements of the subconscious, which was thought to be potentially 
useful in those failing to make progress in psychotherapy. Physiological toxicity was not 
observed, even after very large overdose. However, initial testing of psychedelics in patients 
with schizophrenia showed that they were not helpful, exacerbating psychotic symptoms 
and failing to lead to clinical improvement. Trials in depressive, anxious, obsessive and 
addictive disorders were more encouraging, with the psychedelics noted to have 
therapeutic potential within psychologically supportive contexts(Eisner and Cohen, 1958) 
and a low risk of toxicity(Cohen, 1960). By the end of the 1960s, hundreds of papers 
described the use of mescaline, psilocybin and (most frequently) LSD in a wide variety of 
clinical populations with non-psychotic mental health problems(Grinspoon and Bakalar, 
1981).  
 
However, as the psychedelics diffused into wider society and recreational use increased, 
some individuals reported a variety of ongoing symptoms including visual distortions, 
flashbacks and other symptoms that occurred long after the drugs had left the body. This 
came to be classified as ‘Hallucinogen Persisting Perceptual Disorder’(Halpern and Pope, 
2003). Unethical and covert use of psychedelics along with a general hardening of socio-
political attitudes towards drug use contributed to the decision to place psychedelics in 
Schedule I of the 1967 UN Convention on Drugs. Medical use ceased and research dwindled 
until the turn of the millennium, since when a steady renaissance of clinical and academic 
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interest in the psychedelic drugs has returned, reflected by a socio-political narrative that 
has increasingly questioned the relative benefits and harms of the so-called ‘war on 
drugs’(Godlee and Hurley, 2016; Hari, 2015). 
 
This paper presents a synopsis of selected clinical studies with psychedelics performed 
before 1970 and all major clinical studies since the turn of the millennium. We discuss the 
controversies and practical considerations in designing modern clinical trials with 
psychedelics and review the formidable legal and regulatory hurdles that must be overcome 
if psychedelics are to become licensed medicines in psychiatry again. 
 
Pre-Prohibition Clinical Studies 
1895-1940. Studies with Mescaline 
The first medical report of use of a classical psychedelic in Western medicine was made by 
Prentiss and Morgan in the United States in 1895, who reported the ceremonial use of 
buttons of the peyote cactus by indigenous people in Central America(Prentiss and Morgan, 
1895). Mitchell, reporting in the British Medical Journal in 1896, reports self-
experimentation with peyote, describing closed-eye visual experiences and commenting 
that ‘for the psychologist this agent should have value’(Mitchell, 1896). This was a view 
repeated by Havelock Ellis in 1897, describing the experience as ‘…mainly a saturnalia of the 
specific senses, and chiefly an orgy of vision…it is of no little interest to the physiologist and 
psychologist’(Ellis, 1897). 
 
Whilst Arthur Heffter isolated the active component of peyote (mescaline) in 1897, there is 
limited further mention of it in the English medical literature until 1913, when Alwyn Knauer 
administered mescaline by subcutaneous injection to himself and other volunteering 
physicians(Knauer and Maloney, 1913). Knauer had worked as an assistant to the 
psychiatrist Emil Kraeplin who, aside from his involvement in the inception of psychiatric 
diagnosis, was also interested in the effects of psychoactive drugs in producing 
psychopathology. However, his experimentations were restricted, according to Knauer, to 
‘substances, which…produce mental states which have little similarity to actual insanities’. 
Administering mescaline repeatedly both to themselves and other volunteering physicians, 
they commented, ‘Soon after the onset of the visual hyperesthesia, to nearly all the 
investigated persons, out of total darkness, kaleidoscopic pictures appeared.’ Whilst 
commenting on the ‘…vividness of the [visual] hallucinations…they came unsought, they 
were uncontrollable…’ they also noticed that ‘the independence of the hallucinations to 
thought and will was never quite absolute.  On the nature of the conscious experience under 
mescaline, they noted that it ‘…remained practically unclouded…somewhat similar 
to…consciousness in hypnosis’(Knauer and Maloney, 1913). Whilst the nature of 
hallucinations in psychosis remained opaque, Knauer and Maloney recognised that the 
mental state induced by mescaline bore some similarity to the psychotic state.  
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Heinrich Kluver, in 1926, again experimenting on himself, commented, in addition to the 
established visual imagery, on changes in ‘object-awareness’ and ‘self-awareness’ (referred 
to in the original German ‘gegenstandsbewusstsein’ and ‘ichbewusstsein’): 
‘My body and its organs seemed to be most of the time non-existent or detached 
from me as a perfectly functioning machine. While speaking I seemed to listen to a 
speech apparatus…In general, the line of demarcation drawn between ‘object’ and 
‘subject’ in normal state seemed to be changed. The body, the ego, became 
‘objective’ in a certain way, and the objects became ‘subjective’. They became 
subjective not only in the sense that they behaved as visionary phenomena, but also 
in the sense that they gained certain affective qualities…There is no doubt that these 
changes in ‘Gegenstands- und Ichbewusstsein’ are comparable to those observed in 
schizophrenia’.(Kluver, 1926) 
 
In 1936, Erich Guttman, then working at The Maudsley Hospital in the United Kingdom in 
London, raised the possibility of a therapeutic effect of mescaline(Guttmann, 1936). He, and 
a variety of other colleagues, gave the drug to an undisclosed number of ‘medical students’, 
‘undergraduates’, ‘normals’, ‘psychopathic patients’, ‘manic-depressives’, ‘schizophrenics’, 
‘depressives’, ‘morphinists’ and those suffering from ‘derealisation’ and ‘depersonalisation’ 
phenomena(Guttmann, 1936). Not publishing any sort of objective results, he nonetheless 
made the first observation of the potential therapeutic utility of the mescaline-induced 
state in psychotherapy, noting: 
‘There is reason to suppose that patients in such a state may be very susceptible to 
psychotherapeutic influence…If it is so, the intoxication could be made use of as a 
sort of forced or concentrated analysis’. 
Similarly, he recognised the importance of the drug for psychiatrists attempting to 
understand… 
‘…the complicated interplay of aetiological factors in the origin of psychoses. Careful 
analysis of one intoxication like mescaline promises a reliable basis for knowledge in 
the field of toxic psychoses generally, and perhaps hints for the solution of the great 
problem of psychiatry, that of schizophrenia.’ 
 
1940-1970. Studies in Psychotic Diagnoses 
Perhaps because mescaline was never marketed (it was first synthesised by Ernst Spaff in 
1919 and then manufactured by the pharmaceutical company Merck as a research 
chemical), but perhaps also because of the predominance of psychoanalytic theory at the 
time, its use by psychiatrists was sporadic and infrequent. In contrast, after Hofmann 
synthesised LSD in 1943, not only did Sandoz provide it free of charge to psychiatrists, but it 
came at the same time as the emerging idea that psychiatric states might have biological, 
rather than psychological, aetiologies. Moreover, regulation of the medical community, and 
of medical research, was minimal. Growth of interest in LSD was rapid.  
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In 1950, Busch and Johnson(Busch and W. C. Johnson, 1950), working in Missouri, United 
States, published one of the first studies using LSD in patients. They gave 21 patients, mostly 
hospitalised with schizophrenic or manic episodes, LSD. They observed that all patients 
showed ‘increases in activity’, particularly those with mania. Based on these observations 
they gave LSD to a further 8 patients. 3 had diagnoses of catatonic schizophrenia, 4 
‘psychoneurosis’ and 1 ‘psychosomatic’. Describing the results narratively,  
‘The effect…disturbed the barrier of repression and permitted a re-examination of 
significant experiences of the past, which sometimes were lived with frightening 
realism. With this, some of the patients were then able to re-evaluate the emotional 
meaning of some of their symptoms, and improved. Most were better able to 
organize their ideas in relation to real rather than fancied problems and were seen to 
experience and express relevant emotion. Two of the patients [both 
psychoneurotic]…were improved sufficiently to discontinue treatment…’ 
 
In a further group of 59 individuals with schizophrenia divided into 17 with 'pseudoneurotic' 
schizophrenia, 26 with 'undeteriorated' schizophrenia and 16 with 'deteriorated' 
schizophrenia, Paul Hoch and colleagues variously administered LSD and mescaline(Hoch et 
al., 1952). Not recording any objective data, they commented that the drugs ‘markedly 
aggravated’ the mental symptomatology of the individuals they studied. Those with 
‘deteriorated’ schizophrenia showed ‘catatonic withdrawals’ in response to the drugs. 
Whilst noting the propensity of the drugs to uncover new material, the therapeutic value of 
the drugs in this patient group was considerably doubted. This was echoed in studies by 
Liddell(Liddell and Weil-Malherbe, 1953) and Pennes(Pennes, 1954), who observed 
worsening in those with undeteriorated and deteriorated forms of schizophrenia, but 
improvement in some with ‘pseudoneurotic’ forms of schizophrenia. ‘Pseudoneurotic 
schizophrenia’ is an archaic term that included a multitude of depressive, anxious and 
obsessive symptomatology. None of these reports include details of follow up. 
 
Making some attempt at follow up, Herman Denber and Sydney Merlis gave 500mg 
mescaline intravenously to 25 patients with schizophrenia. Whilst 1 patient achieved 
‘complete remission’ from her symptoms (and was well at 1 year follow) and 3 patients 
showed temporary remission of symptoms, psychotic symptoms were either reactivated or 
worsened in the remainder(Denber and Merlis, 1955). In another study published in 1957, 
Sidney Merlis gave 24 patients with chronic schizophrenia between 500 and 750mg of 
mescaline and noted that 1 ‘improved sufficiently to be discharged’, 7 ‘temporarily’ 
improved and in the remainder ‘no change’ was noted(Merlis, 1957). Reporting of adverse 
events or those that worsened with treatment was not included in the report. He concluded 
that mescaline was not a clinically effective agent in schizophrenia. 
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After the early 1960s, clinical studies of the use of LSD and mescaline in psychosis rapidly 
diminished as it became clear that the drugs exacerbated the symptoms of most and did not 
lead to clinical improvement. However, the differences between the psychosis characterised 
by schizophrenia and the state characterised by LSD was still of interest. Langs, in 1968, 
published a detailed questionnaire study comparing schizophrenic patients and healthy 
controls who were randomly assigned to be given LSD or placebo(Langs and Barr, 1968). 
They noted that those with schizophrenia manifested ‘somatic and persecutory delusions 
and hallucinations which qualitatively extended far beyond anything reported by our LSD 
subjects’. Nonetheless, ‘‘paranoid schizophrenics’ responses resembled those of LSD-25 
subjects in regard to feelings of unreality, loss of controls, changes in the meanings of 
experiences, and suspiciousness; they did not, however, exhibit the body image changes and 
elation-related effects found in many of the drug subjects.’ It was noted that the 
hallucinatory element of the LSD experience tended to be largely visual in nature, whereas 
in the schizophrenic state auditory hallucinations predominated. 
 
1940-1970. Studies in Neurotic Disorders 
Ronald Sandison, then working at the Powick Mental Hospital near Worcester, United 
Kingdom, published a paper in 1954 in which 36 patients with predominantly 
‘psychoneurotic’ disorders were treated with variable doses of LSD over a variable interval, 
usually weekly, in the context of psychotherapy(Sandison et al., 1954). LSD dosage was 
started at 25mcg and then increased until an ‘adequate’ reaction was observed. This paper 
described the ‘psycholytic’ method of psychedelic psychotherapy: using LSD within the 
context of psychotherapy to ‘loosen’ ego defences and catalyse access to traumatic 
material. 27 out of 30 with more classical neurotic and depressive disorders were reported 
to have benefited from the intervention, although this was a subjective judgement made by 
the treating clinician, there was no control group and no details of those patients who 
worsened with the treatment. 
Reporting an extension of their research in a publication in 1957, Sandison reported 6 
month follow up in 93 patients with ‘severe neuroses’(Sandison and Whitelaw, 1957). Of 
these 93 (of which 30 were also included in the original 1954 paper), 21 (22.6%) were 
‘recovered’, 20 (21.5%) were ‘greatly improved’, 20 (21.5%)were ‘moderately improved’ and 
32 (34.4%) ‘not improved’. Again, there were no objective measurements, no control group 
and no information on those who worsened in this study. 
Chandler and Hartman, working in California, published a work in 1960 in which 110 
patients with predominantly ‘psychoneurotic’ and ‘personality disorder/trait’ diagnoses 
were given a total of 690 psychotherapy sessions using LSD, usually given in gradually 
escalating dosages between 50mcg and 150mcg(Chandler and Hartman, 1960). They also 
commented on the therapeutic utility of music in ‘…helping to bring out affectively charged 
memories and fantasies’. Experiences under LSD were likened to ‘a waking dream’ with the 
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aim of therapy ‘…to understand it in terms of its emotional meaning rather than to worry 
about its objective validity.’ Of these 110 patients, 50 showed ‘considerable’, ‘marked’ or 
‘outstanding’ improvement, 38 showed ‘some’ or ‘slight’ improvement and 22 showed ‘little 
or no change’ or were ‘slightly worse’. No patients were judged to be ‘definitely worse’. No 
control group was reported. 
 
Attempting to provide a control group, Whitaker, working in Australia, described the use of 
an average of 3.28 LSD psychotherapy sessions in the treatment of 100 patients, comparing 
those treated with LSD psychotherapy to a group of patients treated in years previous to the 
study that were similar in terms of diagnosis and duration of illness(Whitaker, 1964a; 
1964b). Of the 100 patients, 49 had ‘psychoneuroses’, 27 ‘personality disorder’, 21 ‘sexual 
disorders’ and 3 ‘residual schizophrenia’. Outcomes reported were clinician and patient 
agreements of improvement, divided into ‘successful’, ‘borderline’ and ‘failure’. Of the 100 
patients undergoing LSD therapy, 47 were judged to be successful outcomes, 18 borderline 
and 35 failure. In the control group 12 were judged to be successful, 30 borderline and 58 
failures. The rate of success was observed to be higher (75%) in those with the shortest 
duration of illness (0-2 years) as compared to those with the longest (more than 21 years), 
where only 37% were classed as successes. Of those 35 who were deemed as treatment 
failures, 19 ‘evaded’ ongoing therapy after their first LSD experience. None of the 3 residual 
schizophrenics were judged to have improved, however ‘a successful result was obtained in 
more than half the cases of anxiety state, hypochondriasis, hysterical personality, antisocial 
character disorder, anorexia nervosa and exhibitionism’. Outcome data was based on 
subjective judgements and the results were not analysed statistically. 
 
Probably the largest studies of the therapeutic utility of psychedelics in the pre-prohibition 
era were carried out at the Spring Grove State Hospital and the Maryland Psychiatric 
Research Center, both in Baltimore, Maryland, United States during the 1960s and early 
1970s. Reporting on a total of 243 patients with a variety of non-psychotic psychiatric 
diagnoses that included anxiety and depressive disorders, personality disturbances and 
alcohol addiction, Charles Savage and colleagues also pointed out ‘the crucial importance of 
non-drug variables as determinants of reactions to chemical agents [which is] not confined 
to the psychedelics…’(Savage et al., 1967). They administered LSD without the context of 
formal psychotherapy. LSD at a dose of 200-300mcg was given, with mescaline at a dose of 
200-400mg given to potentiate the effect in some patients. Emotional support and 
companionship was provided by a male and female sitter, but with no attempt made at 
interpretation of material. Follow up was the next day, then at 1, 2, 4, 8, and 12 weeks and 
finally at 6 months. A questionnaire was then sent, retrospectively, to the first 113 patients 
in the sample. Ninety-three replied. 83% reported ‘lasting benefit’ and this was found to be 
‘highly correlated (tetrachoric r=0.91) with the report of a greater awareness of an ultimate 
reality’. The claimed improvement rate was 76% at one to three months post LSD, and 85% 
in the three to six months after LSD, this remaining constant after 12 months. Clinician 
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ratings of improvement were made in retrospect by 4 raters, with improvement ratings 
divided into ‘worse’, ‘none’, ‘some’, ‘substantial’ and ‘marked’. Of 243 patients, 197 (81.1%) 
were judged to have improved to some degree: 35.8% showing ‘some’ improvement, 26.3% 
showing ‘substantial’ improvement and 18.9% showing ‘marked’ improvement. Of the 
remainder, 16.9% showed no improvement and 2.1% were ‘worse’. 
 
1940-1970. Studies with Alcoholism 
Clinical studies using LSD in the treatment of alcoholism before 1970 benefited from a more 
systematic approach than other disorders, probably because drinking behaviour is easier to 
quantify objectively. Several reasonable quality controlled studies were undertaken, 
particularly during the latter 1960s, however initial studies were usually uncontrolled. For 
example, Maclean and colleagues gave 61 alcoholics and 39 patients with other diagnoses 
400-1,500mcg LSD on an undisclosed number of occasions, following them up for up to 18 
months(Maclean et al., 1961). Whilst noting that, of the alcoholics, 30 were ‘much 
improved’, 16 were ‘improved’ and in 15 there was ‘no change’, there was no comparison 
control group.  
 
In another study that included a comparison group, Jensen gave LSD to 58 alcoholics on an 
inpatient unit in Ontario, Canada, comparing this to 35 alcoholics given group 
psychotherapy and 45 receiving ‘standard’ care from psychiatrists not connected to the 
study(Jensen, 1962). By chi square analysis, they reported a significant difference in rates of 
abstinence between those given LSD and those given group psychotherapy and standard 
care. However, the control groups were not matched and the authors stated that the group 
treated with LSD were composed of people who remained in follow up, whereas the control 
groups included those lost to follow up. The methods of statistical analysis, chi square 
statistic and p value for significance were also not stated. 
 
More systematic studies were published after 1965, often with non-significant results. 
Smart et al, in 1966, reported the effect of a single LSD experience under controlled 
conditions on the behaviour of 30 alcoholics who were either inpatients or outpatients in 
Toronto, Canada(Smart et al., 1966). They were randomised to a control group that received 
standard care including psychotherapy, a group who received standard care plus a 60mg 
dose of ephedrine sulphate (a drug chosen because it shares some similar subjective effects 
to LSD but with no known efficacy in alcoholism), and standard care plus an 800mcg dose of 
LSD. Drug treatments were administered on a psychiatric ward, with participants kept 
overnight. Otherwise treatment was the same. Both participants and therapists were blind 
to treatment allocation. Nonetheless, in 19 out of the 20 drug sessions, the therapists 
correctly guessed the drug condition. Baseline and 6 month follow up alcohol use data was 
collected in all groups by a participant- and researcher-rated questionnaire. Researchers 
following up participants at 6 months were blind to treatment and analyses were completed 
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prior to blinding being broken. No significant differences were observed between the 
groups in terms of pragmatic measures of alcohol misuse. 
 
Hollister et al, working in 1969 at the Veterans Administration Hospital in California, USA, 
reported the results of a controlled comparison of 72 male inpatients with alcoholism 
randomised to a single dose either of 600mcg LSD or 60mg of dextroamphetamine (Hollister 
et al., 1969). Music and low lighting was provided and a research assistant was available for 
reassurance, but no attempt at psychotherapy was made. Baseline and follow up 
measurements of drinking and associated social effects were recorded with a scale designed 
and validated for the trial. Follow up data was collected at 2, 6 and 12 months post 
treatment by a researcher blind to treatment and independent of the treatment 
programme. Of the 72 patients, 20 had dropped out at 2 month follow up (10 in each group) 
and 27 had dropped out of follow up by 6 months (11 in the LSD group and 16 in the 
dextroamphetamine group). In terms of mean change of questionnaire scores, analysed by 
ANOVA, those in the LSD group were significantly improved over the dextroamphetamine 
group (F=8.5, p<0.01), however the difference was not significant at 6 month follow up. 
Those who dropped out did not differ significantly in baseline scores compared to those 
who did not. At 12 month follow up, only 17 patients remained in the LSD group and 12 in 
the dextroamphetamine group, and the authors considered analysis of this group 
unproductive. 
 
Ludwig et al, working at the Mendota State Hospital in Wisconsin, USA, published in 1969 a 
study in which 176 male inpatients with alcoholism were randomly allocated to one of three 
LSD treatments and a control condition (44 participants per group)(Ludwig et al., 1969). All 
participants allocated to the LSD groups received 3mcg per kg of body weight, with the 
treatments differing by the nature of therapy offered during the LSD experience. One group 
received LSD plus hypnosis plus psychotherapy, a second group LSD plus psychotherapy and 
a third group LSD alone. The fourth ‘control’ group were required to spend an equivalent 
amount of time in the treatment room by themselves, but no intervention was otherwise 
given. Therapists were not blind to treatment group. Evaluation was with a variety of 
symptomatology, drinking behaviour and social adjustment inventories taken at baseline 
then immediately post-treatment and at 3, 6, 9 and 12 months after treatment. Researchers 
collecting follow up data were blind to treatment allocation. All groups showed consistent 
improvements and no significant difference was found between the LSD groups and the 
control groups.  A similar approach, and non-significant result, was found in two further 
controlled studies by Bowen(Bowen et al., 1970) and Tomsovic(Tomsovic and Edwards, 
1970), with borderline significant results found by Pahnke(Pahnke et al., 1970).  
 
Meta-analysing the previous 6 studies, Krebs and Johansen found that LSD treatment was 
significantly associated with maintained abstinence at 1-3 months (OR=2.07 95% CI, 1.26 – 
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3.42; p=0.004), but by 6 months statistical significance was lost (OR, 1.42, 95% CI, 0.65-3.10, 
p=0.38)(Krebs and Johansen, 2012).  
 
Clinical Trials Prior to Prohibition: Discussion 
Studies of the clinical utility of psychedelics published prior to 1970 were, like many studies 
of that time, methodologically suboptimal. A non-exhaustive list of the obvious problems 
includes the following: 
1. Treatment groups were inadequately and inconsistently defined 
2. Treatments were inconsistently applied amongst groups 
3. Control groups were often absent 
4. Attempts to blind study teams were usually absent 
5. Outcome measures were not validated 
6. Outcome data was inconsistently reported 
7. Adverse outcomes were often not reported 
8. Statistical analysis of results was often absent 
9. Power calculations were not used to estimate sample sizes needed to detect an 
effect 
 
Nonetheless, the pre-prohibition research strongly suggested that psychedelic drugs were 
not useful for those with established psychotic disorders and should probably be avoided in 
those liable to develop them. Worsening of psychotic symptomatology was observed in 
most of those with pre-existing schizophrenia and whilst the occasional case was observed 
to recover, no trial reported improvements that might not otherwise have been attributable 
to the passage of time. 
 
Reports were more encouraging in trials with so-called ‘psychoneurotic’ disorders, a term 
which covers a wide variety of anxious, obsessive and depressive states. We have 
systematically reviewed trials in broadly defined unipolar mood disorder in another work, 
which showed that nearly 80% of participants in these trials were judged to have ‘improved’ 
by their clinicians(Rucker et al., 2016). The data was not of sufficient quality to meta-analyse 
and clinical improvement was usually a subjective judgement, rarely based on objective or 
validated scales. Indeed, initial trials were usually little more than case series reported by 
clinicians who probably had positive expectations about treatment. Studies in later years 
suggest more moderate preconceptions, but still reported subjectively defined efficacy in 
many cases. However, in controlled trials with alcoholism, borderline or non-significant 
findings were often reported. Given the lack of power calculations, this may reflect a lack of 
power to detect an effect or a true lack of efficacy. Krebs and Johansen’s meta-analysis of 
these studies suggests the former, at least in the use of LSD in the treatment of alcohol 
dependent individuals(Krebs and Johansen, 2012). 
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Side effects, or adverse events, during the experience were generally not reported 
systematically, if at all. Interpretation of an adverse event varied according to research 
team, particularly for mental phenomena, ranging from a directly toxic action of the drug on 
the brain, which tended to cluster within studies of those with schizophrenia, to the 
expected expression of repressed trauma, which tended to cluster within studies of those 
with neuroses and alcoholism. This may reflect different clinicians’ preconceptions about 
mental illnesses and the aetiologies of behaviours as much as it reflects the effect of the 
drugs. We have listed reported adverse events (non-exhaustively in view of space) in table 
1. Immediate adverse events were more often reported than delayed adverse events. In no 
particular order (frequencies were rarely reported), headaches, palpitations, 
gastrointestinal disturbances, changes in temperature perception, feelings of tremulousness 
or dizziness, and a variety of other somatic complaints were most commonly reported.  
 
A consistent theme was a disparity between the degree of subjectively reported physical 
symptoms and objective changes on medical examination, which tended to reveal only 
minor increases in pulse rate and blood pressure along with pupillary dilatation and, 
occasionally, signs of body temperature changes (shivering and piloerection, or sweating). 
The significance of this disparity is uncertain, however may represent both an increased 
subjective awareness and sensitivity to bodily sensations under the influence of 
psychedelics, as well as drug induced changes in the autonomic nervous system itself. 
 
Sidney Cohen, in 1960, attempted to systematically investigate the incidence of adverse 
events during treatment with psychedelics by sending a questionnaire to 62 investigators 
who were using LSD or mescaline in healthy subjects or patients(Cohen, 1960). 44 
investigators replied. The data covered almost 5,000 individuals given LSD or mescaline on a 
total of more than 25,000 occasions. No instance of physiological toxicity was reported. Of 
those with pre-existing psychiatric problems receiving LSD or mescaline, the rate of 
attempted suicide was 0.12%, completed suicide, 0.04% and psychotic reactions lasting over 
48 hours, 0.18%. The rate in healthy subjects was 0%, 0% and 0.08% respectively. No 
instance of addiction was reported. The instances of these serious events appear rather low 
and the study can be criticised for relying on the recall of clinicians who may have 
underestimated (or been unaware of) the nature and degree of adverse reactions in their 
subjects, particularly in those lost to follow up (who probably had a higher risk of 
experiencing them). 
 
In a narrative report of nine cases who had suffered a variety of persistent psychotic and 
neurotic symptoms after recreational use of, or medical treatment with, LSD, Cohen and 
Ditman concluded that complications were ‘much more likely to occur after the 
unsupervised or inexpert use of the drug.’ Whilst the study was unsystematic, the majority 
of cases occurred using illicit LSD taken within a psychologically destabilising milieu that also 
included other psychoactive drugs and lack of access to timely medical assistance(Cohen 
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and Ditman, 1963). This was a view echoed by Strassman in a comprehensive review of 
adverse events to psychedelics in 1984(Strassman, 1984).  
 
As recreational use of LSD and mescaline increased in the 1960s, so evidence of toxic 
psychological reactions in sensitive individuals accumulated, with occasional tragic 
cases(Keeler and Reifler, 1967) accompanied by sensationalist media reporting. This 
paralleled investigation of psychedelics as so-called ‘truth drugs’ or chemical weapons, 
particularly by the Central Intelligence Agency(Lee and Shlain, 2007). An immoral failure, 
these experiments (and the public outcry over them) accompanied a more general 
hardening of socio-political attitudes towards psychoactive drugs. Moreover, unethical 
medical use of psychedelics doubtless occurred in some centres. Whilst documentation is 
patchy, concerns about this issue were reflected in a legal ruling in Denmark, where the ‘LSD 
Damages Law’ was enacted in 1986. This led to a series of 151 patients gaining 
compensation in the 1980s and 1990s for a variety of psychiatric symptomatology that was 
presumed (but not proven) to have resulted from LSD treatment that was claimed 
sometimes to have been given under coercion, or without informed consent(Larsen, 2016). 
A critique of the report of these cases has recently been published(Erritzoe and Richards, 
2017).  
 
In summary, the research conducted prior to 1970 suggests that whilst there was certainly 
clinical interest in the therapeutic potential of psychedelics in patient populations with non-
psychotic mental health problems, a firm conclusion about efficacy and safety was not 
reached prior to legal sanction that was largely socio-political in motivation, although also 
reflected medical concerns about the sequelae of recreational use. It is within this 
agnosticism and strict regulatory framework that the modern resurgence of research 
interest has taken place and to which we now turn. 
Modern Clinical Studies 
In 1967, psychedelics, including mescaline, psilocybin and LSD, were classified under 
Schedule I of the 1967 UN Convention on Drugs. This legally defined them as having no 
accepted medical use and the maximum potential for harm and dependence. Successive 
national legislation throughout the Western world tended to mimic the 1967 UN Schedules. 
Medical use of psychedelics ceased quickly because doctors were no longer permitted to 
prescribe them. Without a clinical focus, research dwindled almost to a standstill in the late 
1980s and 1990s. This is depicted graphically in figure 1, which shows the annual number of 
publications listed in the database PubMed where the title refers to a classical psychedelic 
drug, expressed as a proportion of all PubMed publications annually, from 1950 to 2016. 
 
<<FIGURE 1 ABOUT HERE>> 
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The herald to modern clinical research using psychedelics were three papers investigating 
the effects of mescaline, dimethyltryptamine and psilocybin in healthy volunteers by, 
respectively, Leo Hermle et al. in Germany(Hermle et al., 1998), Rick Strassman et al. in the 
United States(Strassman and Qualls, 1994), and Franz Vollenweider et al. in 
Switzerland(Vollenweider, 1997). These studies formed the basis for a resurgence of further 
studies in healthy volunteers focussing on neuroimaging(Carhart-Harris et al., 2012; 2016b; 
Daumann et al., 2010; Muthukumaraswamy et al., 2013; Palhano-Fontes et al., 2015; Preller 
et al., 2017; Riba et al., 2004; 2006; Vollenweider, 1997), psychopharmacological(Kometer 
et al., 2012; Preller et al., 2017; Valle et al., 2016; Vollenweider et al., 1998) and 
neuropsychological(Carter et al., 2007; Gouzoulis-Mayfrank et al., 2005) correlates of the 
psychedelic state. This literature is beyond the scope of this clinically focussed review. 
 
The first modern clinical trial investigating the safety and feasibility of using a psychedelic 
drug in a psychiatric patient population was published by Francisco Moreno and colleagues, 
working at the University of Arizona in the United States(Moreno et al., 2006). Nine subjects 
with treatment resistant obsessive compulsive disorder and no other major psychiatric 
pathology were given up to 4 different doses (25, 100, 200, 300 mcg/kg body weight) of 
psilocybin in an open-label design. Treatments were separated by at least 1 week. 29 doses 
were given in total. The Yale Brown Obsessive Compulsive Scale, the Hallucinogen Rating 
Scale and a visual analogue scale measuring overall symptomatology was administered at 0, 
4, 8 and 24 hours post dosing. Whilst significant reductions in OCD symptoms were 
observed in all dosing conditions, there was no significant difference between the different 
dosages of psilocybin, although the trial was likely underpowered to detect an effect. No 
serious adverse events were reported. 
 
Matthew Johnson and colleagues, working at the Johns Hopkins University in Maryland, 
United States, published an open-label pilot trial in 2014 using moderate (20mg/70kg) and 
high (30mg/70kg) doses of psilocybin given to 15 otherwise psychiatrically healthy subjects 
with tobacco addiction undergoing a structured 15-week smoking cessation treatment(M. 
W. Johnson et al., 2014). Psilocybin was given at weeks 5, 7, and 13. Initial psilocybin dosing 
was with the moderate dose and the higher dose offered, but not enforced, in the 
subsequent sessions. A total of 19 meetings took place as part of the smoking-cessation 
programme and psilocybin delivery. Biological markers of smoking cessation were assessed 
at baseline, weekly throughout the treatment intervention and at 6 monthly follow up. A 
total of 42 psilocybin sessions were delivered. No clinically significant adverse events were 
reported during the treatment or follow up. 12 of 15 (80%) of participants were abstinent 
from tobacco as measured by biological markers at 6 month follow up. Whilst this was 
highly significant when pre and post treatment self-reported smoking figures were 
compared statistically, the authors were measured in their interpretations given the open 
label design and low numbers of participants. 
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In a further open-label pilot study in 2015 on addiction, this time to alcohol, Michael 
Bogenschultz and colleagues at the University of New Mexico, United States, gave psilocybin 
to 10 alcohol dependent patients (4 women) in addition to standard motivational 
enhancement therapy(Bogenschutz et al., 2015). Psychological support was given before, 
during and after 2 psilocybin sessions, spaced 4 weeks apart. The total treatment 
intervention was 12 weeks. Outcome data was collected at baseline and for 36 weeks in 
total. The dose of psilocybin used was either 0.3mg/kg or 0.4mg/kg. The primary outcome 
was the percentage of days spent drinking heavily compared between measures taken at 
baseline and weeks 5-12. 9 participants completed follow up. Results suggested, in line with 
studies in the 1960s using LSD in alcoholics, that the acute effects of psilocybin were less 
strong in this group. Large and statistically significant improvements in drinking behaviour 
immediately after treatment were seen and these correlated with the intensity of the drug 
effect. However, the open-label, uncontrolled design suggests caution is needed in 
extrapolating the finding. No serious adverse events were noted. Again, the authors 
concluded that psilocybin was a safe and feasible treatment to deliver in a clinical trial 
setting.  
 
Three pilot studies using psychedelics in major depressive disorder have been published to 
date in the modern literature(Carhart-Harris et al., 2017; 2016a; Osório et al., 2015; Sanches 
et al., 2016). Our own open-label pilot study gave 2 doses of psilocybin (a 10mg “test” dose 
and a 25mg therapeutic dose) 1 week apart with psychological support before and after the 
experience to 20 patients with treatment resistant depression who were moderately to 
severely depressed, but without psychotic features(Carhart-Harris et al., 2017; 2016a). 
Participants were withdrawn from their antidepressant medications prior to psilocybin 
treatment. The primary outcome measure was the mean change in the participant-rated 
quick inventory of depressive symptoms rating scale from baseline to 1 week after the 
second psilocybin treatment. Follow up was for 6 months. No serious adverse events 
occurred. Significant improvements in depression ratings were seen at 1, 2, 3 and 5 weeks, 
and at 3 and 6 month follow up. The maximal effect was seen at 5 weeks (Cohen’s d = 2.3). 
Further treatment seeking by participants after 5 weeks, and particularly after 3 months, 
likely confounded follow up data collected at 3 and 6 months. 5 of the 20 participants 
sought and obtained psilocybin again during the follow up period. The trial established 
feasibility in this patient group and initial evidence of safety, but efficacy interpretations are 
precluded by the open-label, uncontrolled design. 
 
Flavia de Lima Osorio and colleagues(Osório et al., 2015) and Rafael Sanches and 
colleagues(Sanches et al., 2016), both working in Sao Paulo, Brazil, reported studies where a 
single dose of ayahuasca to patients with recurrent depression. In Osorio’s pilot study, 6 
medication and ayahuasca naive participants (4 women) were given 2.2ml/kg of a 
standardised preparation of ayahuasca containing 0.8mg/ml DMT and 0.21mg/ml of 
harmine. Measurement of depressive symptoms was with the clinician rated Hamilton 
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Depression Rating Scale (HAMD) and the Montgomery Asperg Depression Rating Scale 
(MADRAS). Baseline measurements were compared with measurements taken at 1 day, 1 
week, 2 weeks and 3 weeks after treatment. Significant reductions in depressive symptoms 
were seen at 1 day, 1 week, 3 weeks but not 2 weeks after treatment, both with the HAMD 
and MADRAS. The treatment was administered safely without any serious adverse events. 
Sanches and colleagues conducted a follow up to this work with an open-label study on 17 
patients with recurrent depressive disorder given the same dose of ayahuasca, with 
identical outcome measures. Again, significant reductions in depressive symptoms were 
observed up to the three-week end point of follow up. The treatment was well tolerated 
with no serious adverse events. The failure to collect participant rated scales of depressive 
symptoms and the open-label design precludes clinical interpretation beyond feasibility and 
safety.  
 
Finally, four separate studies have been published on the use of psychedelics in end-of-life 
anxiety associated with life threatening illness(Gasser et al., 2014; Griffiths et al., 2016; Grob 
et al., 2011; Ross et al., 2016). Charles Grob and colleagues, working in California, United 
States, gave 12 subjects (11 women) a moderate (0.2mg/kg) dose of psilocybin and an active 
placebo (niacin 250mg) several weeks apart with psychological support in a double-blind 
design in which subjects acted as their own control(Grob et al., 2011). All subjects had 
advanced cancer diagnoses and DSM-IV defined acute stress disorder, generalised anxiety 
disorder, or adjustment disorder with anxiety because of the cancer diagnosis. Four subjects 
were psychedelic naive. All 12 completed 3 month follow up. Non-statistically significant 
trends towards improvements in mood were observed. The treatment was well tolerated 
with no serious adverse events. 
 
Peter Gasser and colleagues, working in Switzerland, gave LSD to 12 patients with anxiety 
associated with life threatening disease in a double-blind, randomised, active placebo 
controlled pilot trial(Gasser et al., 2014) with a 12 month qualitative follow up study also 
reported(Gasser et al., 2015). Drug free psychotherapy sessions were supplemented by two 
LSD assisted psychotherapy sessions given 2-3 weeks apart, in which participants were 
randomised to receive either 200mcg or 20mcg of LSD. An open label extension was offered 
to those randomised to the 20mcg dose. The State Trait Anxiety Inventory was used as the 
outcome measure. Significant reductions were found in state, but not trait, anxiety at 2 
months, sustained at 12 months. The treatment was delivered safely with no serious 
adverse events. This is the only modern trial to our knowledge that has used LSD in patients. 
 
Two larger, double blind, randomised, placebo-controlled crossover trials investigating the 
efficacy of psilocybin in the treatment of anxiety and depression in patients with life-
threatening cancer diagnoses were published from two separate groups in the United States 
in 2016(Griffiths et al., 2016; Ross et al., 2016).  
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Working in New York University, Stephen Ross and colleagues gave 29 patients a single dose 
of 0.3mg/kg psilocybin or 250mg niacin, both in conjunction with psychotherapy. Crossover 
occurred at seven weeks. 2 therapists worked with each patient and extensive psychological 
support and therapy was provided. A variety of clinician and participant rated measures, 
including the State Trait Anxiety Inventory and the Beck Depression Inventory, served as 
primary outcome measures and were collected at 1 day prior to the first dose, 1 day, 2 
weeks, 6 weeks and 7 weeks after the first dose, then 1 day, 6 weeks and 26 weeks after 
dose 2. The treatment was delivered safely, with no reports of serious adverse events. The 
group receiving psilocybin showed ‘immediate, substantial, and sustained’ clinical benefits 
as measured by both clinician and participant rated scales that lasted for the 7 weeks prior 
to crossover and were also sustained at the final point of the study, 26 weeks after dose 2 
(approximately 8 months after dosing). The group that received niacin as dose 1 showed 
transient reductions that were not sustained at 7 weeks. After crossover and receiving 
psilocybin, immediate and sustained reductions in anxiety and depression were observed, 
with the effect sustained at follow up at 6 and a half months.  
 
Working in Baltimore, Roland Griffiths and colleagues gave psilocybin using a similar double 
blind, randomised, crossover design to 51 patients with life threatening cancer and 
associated anxiety and depressive symptoms(Griffiths et al., 2016). In this study, the placebo 
condition was a very low dose of psilocybin (1mg or 3mg/70kg) compared with a high 
treatment dose of psilocybin (22mg or 30mg/70kg) administered in a counterbalanced 
sequence with 5 weeks between sessions and 6 month follow up. Thus, those who received 
the low dose of psilocybin first received the high dose second and vice versa. Extensive 
psychological support was provided before, during and after the experience and the average 
length of participation in the study was approximately 9 months. The primary outcome 
measures were the Hamilton Depression Rating Scale and the Hamilton Anxiety Scale, two 
clinician-administered scales. The results showed statistically significant superiority of the 
high dose versus the low dose in terms of the primary outcome measures and self-reported 
measures when data at 5 weeks was considered. There were no serious adverse events 
reported. Because participants crossed over from low to high dose, and vice versa, at 5 
weeks, the blind was effectively broken at this point. Significant associations between 
mystical type experiences and enduring positive changes were observed, reflecting previous 
research done by this group(Griffiths et al., 2008; 2006).  
 
Commentary on both studies pointed out that the crossover design and degree of 
psychotherapy provided around the psilocybin experience may have confounded the effect 
attributed to psilocybin(Sellers and Leiderman, 2017). As ever, trials such as these are often 
subject to the so-called ‘winner’s curse’, whereby effect sizes tend to be inflated in 
pioneering trials of new treatments due to a variety of subtle effects. Future trials are likely 
to report more modest findings. 
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<<TABLE 1 ABOUT HERE>> 
 
Pathways to Licensing: Modern Clinical Trials & Regulatory 
Frameworks 
Clinical trials with investigational medicinal products (IMPs) ultimately have one aim: to 
provide objective data to determine whether the IMP in question is safe and efficacious 
enough to justify a license. In the modern context of research with classical psychedelics, 
the IMP most likely to be licensed is psilocybin. However, the legal, regulatory and 
commercial hurdles to this are formidable. For the remainder of this article we concentrate 
on this process and discuss, within the context of modern trials so far, a strategic approach 
to tackling this challenge. 
 
A license for an IMP results from approval from national medicine’s regulatory bodies. In 
the UK, for example, this is the Medicines and Healthcare products Regulatory Agency. A 
license can be gained via various ‘routes’. For example, existing drugs may be relicensed 
with market exclusivity for rare diseases to drive development in areas that would 
otherwise be commercially non-viable (the ‘orphan’ drug route). However, most drugs are 
developed de-novo for more common diseases based on the commercial potential 
predicated on a limited period of market exclusivity after licensing. Regardless of the route, 
licensing is based on objective data about the IMP’s safety and efficacy in defined patient 
groups. This requires a series of randomised, controlled trials (RCTs) conducted on sufficient 
numbers of participants in a regulated fashion that seeks to collect valid, objective data 
about adverse outcomes and to disambiguate the effects of the IMP from other influences 
on outcome. A licensing decision is made based on a balanced judgement of the risks and 
costs of treatment with the IMP weighed against the risks and costs of the disease itself. 
 
In the modern era, trials are divided into phases 1, 2, 3 and 4. Phase 1 trials are open-label 
and investigate safety in small numbers of healthy human volunteers. Phase 2 trials 
investigate safety and feasibility in modest numbers of patients. Whilst publications that 
result from phase 2 trials often report data about efficacy they are actually more concerned 
with safety and feasibility. They may be open label or controlled and the data is used to 
design phase 3 trials. Phase 3 trials are most usually RCTs and investigate safety and efficacy 
in larger numbers of patients. Data from phase 3 trials often form the mainstay of evidence 
used for licensing decisions. Phase 4 trials are conducted on very large numbers of patients 
after a medicine has been approved and marketed and are designed to detect treatment 
effects and rare side effects that could not reasonably be detected in phase 3 trials. At the 
time of writing, psilocybin is undergoing phase 2 trials, with phase 3 trials in the late stages 
of planning. This leads us naturally to a discussion about the safety of psilocybin and the 
feasibility of the clinical trials with it. 
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Safety 
To date, 146 patients with a variety of psychiatric problems have been treated with 
psilocybin and reported in the modern medical literature. There have been no serious 
adverse events reported in these trials, although the infrequent reports of drop outs suggest 
absence of complete follow up data. A serious adverse event is defined as a reaction that 
results in death, is life threatening, results in prolonged hospitalisation or persistent or 
significant disability. The absence of this so far reflects research with psilocybin in healthy 
volunteers(Studerus et al., 2011), pre-prohibition research with LSD and mescaline(Cohen, 
1960), modern population level data on recreational use of psilocybin mushrooms and other 
psychedelics (Carhart-Harris and Nutt, 2013; Hendricks et al., 2014; 2015; Johansen and 
Krebs, 2015; Krebs and Johansen, 2013a; Nutt et al., 2010; Walsh et al., 2016) and 
toxicology work(Gable, 2004). However, modern trials with psilocybin are notable for not 
collecting adverse event data systematically in a manner that allows aggregated analyses 
across studies. The incidence of adverse events, and particularly hallucinogen persisting 
perception disorder, mania, psychosis, self-harm and suicidal behaviour will need to be 
compared between treatment and control groups, along with assessments about causality. 
A single consolidated database of adverse event information is necessary for regulatory 
approval. A number of groups have recently collaborated in Europe to establish this for 
trials using psilocybin in treatment resistant depression.  
 
We have collated the most common immediate and delayed adverse events reported in the 
literature in table 1. Transient anxiety, nausea, vomiting and mild increases in blood 
pressure and heart rate are the most frequently observed immediate adverse events. 
Headache is the most common delayed adverse event. No cases of prolonged psychosis or 
hallucinogen persisting perception disorder have been reported in modern trials with 
psilocybin, ayahuasca or LSD. Dropout rates have been low, however in these early trials it is 
likely that study samples are a self-selecting group with favourable attitudes towards 
psychedelics, which may be inferred from the proportion reporting previous use. In our trial 
of psilocybin in treatment resistant depression 35% of participants had a lifetime history of 
psilocybin mushroom use. This is less than a recent worldwide survey of 22,289 recreational 
drug users, which found a lifetime prevalence of use of 43.1%(Winstock et al., 2013) but 
more than prevalence figures of 17% for lifetime LSD, mescaline or psilocybin use amongst 
21-64 year olds in the 2010 US National Survey on Drug Use and Health(Krebs and Johansen, 
2013b). 
 
Dependence and Diversion 
There is very limited evidence that psychedelics cause dependence or addiction(Brunton et 
al., 2011; Morgenstern et al., 1994). Euphoria is not a consistent feature of the psychedelic 
experience, tolerance develops quickly and completely and there is no known withdrawal 
syndrome(Buckholtz et al., 1985; Cholden et al., 1955; Isbell et al., 1956). Psychological 
dependence appears to be rare, however research in this area is limited(Blacker et al., 
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1968). Thus psychedelics appear to have a low potential for abuse relative to other 
psychoactive drugs(Fábregas et al., 2010; Gable, 2007). Given the above and the fact that 
psilocybin would be delivered within a controlled healthcare setting rather than the 
community, the risk of diversion of drug supplies in the context of existing security 
measures for other controlled drugs used in healthcare settings appears to be low. 
 
Feasibility of RCTs with Psychedelics 
The ascendency of the RCT, which inherently attempts to separate drug effects from their 
contexts, has its origins in the Kefauver Harris Drug Amendments of 1962, which were 
developed in response to the thalidomide tragedy. However, a common theme in the 
literature is the opinion that psychedelics are therapeutic within a psychologically 
supportive context, rather than therapeutic per se. Given the disparity between the 
mechanism of action of psychedelics and the purpose of RCTs, some have argued that RCTs 
with psychedelics are fundamentally flawed and therefore not feasible(Oram, 2012).  
 
Modern RCTs with psilocybin have shown large effect sizes in distress associated with life 
threatening disease(Griffiths et al., 2016; Ross et al., 2016), however in these studies the 
degree of psychological support provided was large. Criticisms of these trials is based upon 
this, reflecting the wider issue above(Sellers and Leiderman, 2017). At the other extreme, 
Smart et al., in their 1966 study of LSD in alcoholism, tied their participants to a bed with a 
Posey belt and gave them a very large dose of LSD (800mcg) before attempting to engage 
them in a 3-way interview about their alcohol use(Smart et al., 1966). Perhaps 
unsurprisingly (the study was also probably underpowered) negative results were reported. 
A meta-analysis of pre-prohibition trials in alcoholism showed significant evidence of 
efficacy overall(Krebs and Johansen, 2012), however only one pilot study has been 
completed so far in the modern era using psilocybin in alcoholism. This found an 
encouraging effect on drinking behaviour, however again, psilocybin was given in the 
context of quite extensive psychological support and a motivational enhancement 
programme(Bogenschutz et al., 2015).  
 
It appears that the problem of determining the relative contribution of psychedelic and its 
context is a thorny one. However, given that it would be unethical to give psychedelics 
without some sort of psychological and emotional support it seems that this basic milieu is 
the treatment being tested. Thus, it could be argued that the problem lies not necessarily 
within the treatment milieu itself, but rather in the desire, via the RCT, to disentangle 
inherently inextricable elements of a complex treatment, where the overall effect may be 
more than the sum of its disambiguated parts. Trials that attempt to understand how 
different contexts interact favourably, or unfavourably, with psychedelics may be of more 
value than those that attempt to artificially separate them. This argument could be applied 
to many complex disease treatments in medicine. 
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Overall, whilst the motivation of the RCT is, in part, to disambiguate drug effects from 
associated confounds, the principal responsibility of any clinical trial team is to the safety 
and wellbeing of the participants. So, whilst the RCT design is not an ideal fit in trials of 
psychotropic drugs in general (and psychedelic drugs in particular) there appears to be no 
better alternative. Thus, we conclude that this problem should not be an impediment to 
carefully designed trials with psychedelics and, since it would be unethical not to include a 
modest degree of psychological support within the design, the trials are, by definition, 
feasible. This has been demonstrated practically by modern pilot trials. We remain agnostic 
about outcome when the RCT design is applied in phase 3 trials, but agnosticism is 
ultimately why the research is necessary. 
 
Commercial Viability 
Phase 2 trials are relatively inexpensive in comparison to phase 3 trials, which often cost 
many millions of dollars and thus generally require profit-driven commercial investment. 
This usually requires the commercial potential inherent from a legally agreed period of 
patented market exclusivity for the developer. This allows recuperation of development 
costs and generates income that drives further progress. However, since the patent on 
psilocybin (and LSD) has long expired, commercial viability, at face value, seems doubtful. 
Treating psilocybin as an orphan drug is not, at face value, viable because the proposed 
disease areas (such as clinical depression) are not rare enough to fulfil criteria for this route. 
The problem of finance is exacerbated further by the security and bureaucratic 
requirements imposed by Schedule I of the UN Convention on Drugs, which results in even 
more financial burden for trials with psychedelics than non-Schedule I drugs(Nutt et al., 
2013). How can phase 3 trials with psilocybin be funded if there is no commercial potential 
to incentivise that funding? 
 
The answer to this is multi-faceted. Recently, a UK based company announced a multi-
centre phase 3 trial of psilocybin in 300 patients with treatment resistant depression in 
Europe, with significant financial backing from investors, suggesting that the commercial 
potential exists and this particular hurdle may be shortly overcome(“COMPASS - Navigating 
Mental Health Pathways,” 2017). Grant holders in Europe and the US have started to fund 
trials with Schedule I substances over the last 10 years, perhaps suggesting a subtle shift in 
socio-political attitude. Psychedelics tend to capture the imagination of the public (as well 
as the media) and significant sums have been raised through social media-linked crowd 
funding as well as from charitable and entrepreneurial sources(Emerson et al., 2014; 
Nichols, 2014). So, whilst the commercial potential in psilocybin may be somewhat 
atypically predicated, there is accumulating evidence that it now exists in sufficient quantity 
to fund the trials needed to collect evidence to submit to regulators. 
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Schedule I 
With commercial potential, the practical and bureaucratic burdens imposed by Schedule I 
are inconvenient, but not insurmountable. Special licenses are required to process and 
administer Schedule I drugs and strict security protocols are necessary that require special 
infrastructure. For example, pharmacies holding Schedule I drugs in the UK must be 
monitored by closed circuit television at all times and subject themselves to regular 
inspections. Storage containers holding Schedule I drugs must satisfy certain security 
standards and be securely fastened to reinforced walls or floors. 
 
Those teams and institutions that have already conducted trials with psilocybin have 
implemented these requirements and are thus in a good position to conduct further 
research. With precedent comes familiarity and then replication. As the socio-political 
landscape changes, so do the attitudes of grant funders. In combination, this should 
stimulate other research groups to engage with the practicalities of this fledgling field of 
research, where there is, after all, plenty of room for expansion. 
 
Moreover, there is historical precedent of Schedule I drugs being developed for medical use. 
Dronabinol (synthetic delta-9-tetrahydrocannabinol) was approved as an orphan drug for 
AIDS-related anorexia in 1985 and is now also approved for cancer chemotherapy related 
nausea and vomiting(Brafford May and Glode, 2016). Xyrem (sodium γ-hydroxybutyrate) 
was approved for the treatment of cataplexy associated with narcolepsy in 2004(Owen, 
2008). An extract of cannabis sativa (nabiximols) was licensed in 2010 in the UK for 
spasticity in Multiple Sclerosis(Lakhan and Rowland, 2009). Extracts of cannabis are also 
being investigated for certain forms of childhood epilepsy(Hussain et al., 2015). Generally, 
the drug development pipeline is similar and a successful licensing application results in the 
drug being legally rescheduled. At this point, the drug becomes prescribable by medical 
doctors without the need for a special license, breaking the ‘vicious cycle’ of Schedule I 
research suppression(Nutt et al., 2013). With the force of commercial interest behind it, we 
anticipate a similar process for psilocybin if efficacy and safety are confirmed. 
 
Patient Groups 
If trials using psychedelics are commercially and legally viable, then which patient groups 
should be focussed on? In a costs-driven world, it is likely that this will be those associated 
with high socio-economic burden, morbidity and mortality and where effective treatments 
are lacking or burdensome. Within psychiatry, the most logical initial focus is probably 
unipolar depressive disorder, with treatment resistant depression a priority. Unipolar 
depressive disorder is increasingly prevalent(Lopez and Murray, 1998; Murray and Lopez, 
1997; “World Health Organisation,” 2017), confers startlingly high socio-economic 
burden(Greenberg et al., 2015; 1993; McCrone et al., 2008; van Wijngaarden et al., 2004; 
Wang et al., 2003), is under-researched relative to disease burden, related to poorer 
outcomes in a wide variety of physical health problems(Moussavi et al., 2007) and is 
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associated with a 20 fold increased risk of completed suicide(Harris and Barraclough, 1997). 
Of those who have a depressive episode, 85% will go on to have another and successive 
episodes increase the risk still further(Mueller et al., 1999). Treatment resistance, defined as 
failure to respond to at least two antidepressants, is common and longer term, depth 
psychological and social therapies are sufficiently expensive to deliver to make psilocybin 
therapy a viable potential treatment, if safety and efficacy is demonstrated. 
 
Whilst the initial focus of commercially driven trials is likely to be treatment resistant 
depression, the largest modern trials to date have been in psychological distress associated 
with terminal illnesses. Clinical scenarios involving the use of psychedelics in palliative care 
have inherent advantages in the process of gaining regulatory approval, because the safety 
data requirements are not as burdensome in groups where life expectancy is limited. 
Nonetheless, evidence of efficacy is still required and it is not yet clear where the funding 
for phase 3 trials of psilocybin in end of life care will come from. 
 
Given the mechanism of action of psychedelics, the potential scope of application could be 
wide. Functional neurological disorders(Bryson et al., 2017) and anorexia nervosa appear 
interesting candidates for further exploration, for example. However, it is anathema to give 
psychedelics without informed consent, a point that leads us into a final brief discussion of 
the practical aspects of conducting trials with psychedelics such as psilocybin. 
 
Practical Considerations in Clinical Trials with Psychedelics 
Whilst their physiological safety is relatively well established, psychedelics elicit acute 
sensitivity to context and psychologically toxic reactions do occur. Rarely, tragic 
circumstances have occurred(Keeler and Reifler, 1967; Reynolds and Jindrich, 1985), often 
attracting disproportionate media coverage. In the light of this, what practical steps can be 
taken to minimise risks in psychedelic trials? A full discussion of this question has been 
covered elsewhere(M. Johnson et al., 2008), but we present some key points, revolving 
around our experience of using psilocybin in treatment resistant depression. 
 
Recruitment 
Recruitment in trials of psychiatric disorders is inherently difficult as the disorders 
themselves affect motivation and adherence. In addition to this more general problem, 
psychedelics are stigmatised. This combination may lead to selection bias. This can be 
overcome in part by using established clinical databases of patients that have consented to 
research contact, for example our own at King’s College London(Perera et al., 2009; R. 
Stewart et al., 2009). This allows researchers to approach potential participants, rather than 
relying on a self-selecting sample of volunteers contacting the research team. On the other 
hand, self-selecting volunteers may be less liable to experience adverse events to 
psychedelics because of the positive preconceptions that motivate them to volunteer. Post 
hoc comparisons of study samples with case registers can also help determine to what 
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extent study samples may differ to the populations they are drawn from, as well as allowing 
comparisons with ‘treatment as usual’ cohorts. 
 
Screening 
Clinical trials with psychedelics should include adequate procedures to screen out high risk 
individuals. A personal or family history of psychosis, personal history of mania, personal 
history of repeated violence towards others and a recent personal history of suicide attempt 
serious enough to require hospitalisation are sensible exclusions, as is current drug or 
alcohol abuse (unless this is the target for intervention). Medical screening should exclude 
those with serious neurological, renal, liver or cardiac disease. Given psilocybin’s tendency 
to modestly increase blood pressure, uncontrolled hypertension should also be an 
exclusion. Women who are pregnant, at risk of becoming pregnant (inadequate 
contraception) or breast feeding should also be excluded. All participants should be 
registered with a local general or family practitioner and consent to the sharing of their 
records with the study team. Failure to consent to this should raise clinical suspicion about 
motivations for participation. 
 
Concomitant Medications 
Commonly prescribed psychiatric medications should be withdrawn prior to use of 
psychedelics. Sufficient washout time is necessary, particularly for fluoxetine(Burke et al., 
2000). Tricyclic antidepressants, lithium, and acute administration of selective serotonergic 
reuptake inhibitor (SSRI) antidepressants may increase sensitivity to psychedelics(Bonson 
and Murphy, 1996), as may haloperidol(Vollenweider et al., 1998). Chronic administration of 
SSRIs(Bonson, 1996; Stolz et al., 1983; Strassman, 1992) and monoamine oxidase 
inhibitors(Bonson and Murphy, 1996) appear to reduce sensitivity to psychedelics. 
Antagonists of the 5-HT2A receptor (mirtazapine and most antipsychotic drugs) attenuate 
response to psychedelics, as do benzodiazepines, particularly in acute use. The effect of 
antiepileptic drugs is not known.  
 
Psychiatric & Psychological Support 
A psychiatrist with an appropriate Schedule I license is required to prescribe and administer 
the psilocybin, manage other medication, medically monitor the treatment and provide 
assessment and management of mental state and risk during the participant’s journey 
through the trial. At least one session of psychological preparation is required for all 
participants and is probably most effectively delivered by psychotherapists, psychologists or 
counsellors that have experience of the psychedelic state and appropriate training(Phelps, 
2017). Likely effects of the psychedelic should be discussed and attention given to the 
possibility of long forgotten, unknown or emotionally charged material surfacing.  
 
On the day of the treatment, participants should be accompanied at all times, preferably by 
those who provided psychological preparation. Onset with psilocybin starts at about 30 
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minutes, peaks after about 90 minutes and subsides after 4-6 hours, making day case 
treatment viable. A comfortable, supportive environment with easy access to the lavatory is 
recommended. Music is often used to accompany the experience and has been shown to 
enhance the emotional response to psychedelics(Kaelen et al., 2015; 2016). A psychiatrist 
should be available at short notice, but need not necessarily be present. 
 
Dysphoria, confusion, anxiety, agitation, panic and paranoia are all expected reactions in a 
proportion of psychedelic experiences. They are usually mild and respond to simple 
reassurance and attendance to physical pain or discomfort. Rescue medications are a last 
resort, given under the supervision of the psychiatrist. A short-acting benzodiazepine such 
as lorazepam or midazolam is recommended. If rescue medications are used, it may be 
necessary to arrange overnight stay and monitoring in the hospital or clinical research 
facility. Otherwise, participants can leave the research facility accompanied by a friend or 
relative once the clinical team is satisfied that this is safe. 
 
Follow up of participants should include at least one session of psychological support with 
the therapist that has accompanied the participant through the trial. The question of ‘how 
much is enough’ is difficult. In a world where cost-efficiency is prioritised by most 
healthcare providers and given the requirements of regulatory bodies, we suggest that 
support should be minimal. We acknowledge that some may strongly disagree with this 
idea, but believe it strikes the right balance between idealism and pragmatism in the 
context of clinical trials. The trial itself will be a support if it includes regular follow up for 
collection of outcome measure data and psychiatric monitoring. 
 
Blinding 
In common with many trials of psychoactive drugs, effective blinding of psychedelic therapy 
is hard to achieve because the subjective effect is often obvious to participants and 
observers. This creates expectancy effects in both trial participants and researchers that can 
bias outcome measures and inflate effect sizes. This suggests certain elements of trial 
design.  
 
Firstly, blinded ratings of primary outcome measures should be taken by trained raters who 
are blind to treatment allocation. Videos of such ratings allow comparisons across raters 
and calculation of inter-rater reliability scores. Secondly, active placebos should be 
considered. Active placebos can be subthreshold doses of the investigational drug or a 
different drug with a similar (but non-therapeutic) psychoactive effect. Subthreshold 
dosages of the investigational drug have the advantage of simplicity and may be particularly 
effective if participants are not told the different dosing regimens in a trial (although this 
approach may raise ethical issues). However, subthreshold dosages may still be 
psychoactive, potentially reducing statistical power and increasing the likelihood of a type II 
error during analysis. Use of other psychoactive drugs as active placebos, such as 
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methylphenidate, a benzodiazepine, or niacin, has been performed. However, this 
introduces the difficulty of choosing a drug that has a similar subjective effect but is known 
not to have a therapeutic effect. Crossover trials have been performed, but these are 
practically difficult and create problems with statistical analysis because of the putatively 
extended therapeutic effect of psychedelics. There is little consensus on which strategy is 
preferred.  
 
Conclusions 
Psychedelics have a long history of use and yet they attract emotive and often polarised 
opinions in modern Western society. History suggests they may have a place in the 
treatment of refractory neurotic disorders, particularly depressive disorder, anxiety 
disorders, addictions and in the psychological challenges associated with death and dying. 
Psychedelics appear to have a context-dependent mechanism of action. This mandates 
carefully designed trials within safe and comfortable settings staffed with psychotherapists 
and psychiatrists familiar with their use. 
 
Whilst modern pilot studies (largely using psilocybin) have shown promise, treatments with 
classical psychedelics will need to stand up to the scrutiny of the RCT design, which itself 
poses significant challenges. The money to finance RCTs with psychedelics will likely come 
from a mixture of profit-driven driven commercial enterprises, charitable organisations, 
crowd-funding and government. The aim of RCTs is to demonstrate safety and efficacy. If 
safety and efficacy is confirmed, licensing and rescheduling will likely follow. At this point, 
psychedelics will need to demonstrate deliverability and cost-effectiveness if they are to 
become established and accepted treatments. Many treatments fail these tests. Delivery of 
psychedelics in real-world healthcare is likely to be expensive relative to other 
interventions, underlining our opinion that they are best investigated as options for those 
with socioeconomically costly psychiatric problems (such as treatment resistant depression) 
that are refractory to cheaper and more established therapies. 
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Author(s) Year Predominant Diagnosis Sample Population 
Control 
Population Drug/Dosage Efficacy Outcomes Adverse Events (Immediate) Adverse Events (Delayed) 
Maclean et 
al. 1961 Alcoholism 
61 Alcoholism 
11 Personality 
disturbance 
26 Neurosis 
2 Psychosis 
None LSD 400-1,500mcg Yes 
52 'much improved' 
29 'improved' 
19 'no change' 
Frequency not stated. 'Transient nausea', 
'mild headache', 'mild gastric distress'. Not reported 
Jensen 1962 Alcoholism 58 Alcoholism 
35 
Alcoholism - 
group 
therapy 
alone 
45 controls - 
'care’ from 
other 
psychiatrists 
LSD 200mcg Yes 
Significant improvement in 
rates of abstinence for 
alcoholics receiving LSD 
over those receiving group 
therapy or standard care (chi 
square) 
Frequency not stated. 'Anxiety', 'nausea', 
'tension', 'headaches', 'side effects…are 
indicative of emotional conflicts' 
4/58 (6.9%) treated with LSD 
were lost to follow up 
18/35 (51.4%) treated with group 
therapy alone were lost to follow 
up 
23/45 (51.1%) treated by other 
psychiatrists were lost to follow 
up. 
Smart et al. 1966 Alcoholism 10 alcoholism 10 + 10 Alcoholism 
10 - standard care 
10 - standard care plus 
60mg ephedrine 
10 - standard care plus 
800mcg LSD 
No No significant difference between groups Not reported Not reported 
Hollister et 
al. 1969 Alcoholism 36 alcoholism 
32 
alcoholism 
32 - LSD 600mcg 
32 - 60mg 
dextroamphetamine 
Yes 
Superiority of LSD at 2 
months. No significant 
differences at 6 months. 
2 'nausea', 2 'vomiting', 2 'sufficiently 
agitated to require IM admin. of 
chlorpromazine 50mg', 1 'grand mal 
seizure…in a patient with previous history 
of "rum fits"', 1 'moderate confusion 
requiring hospitalisation for 4 days' 
10 (LSD) vs 17 (D'amphetamine) 
drop outs in each group at 6 
months 
1 suicide (group not stated) 
Ludwig et al. 1969 Alcoholism 132 alcoholism 44 
alcoholism 
44 - standard care 
44 - LSD 3mcg/kg 
44 - LSD 3mcg/kg + 
psychotherapy 
44 - LSD 3mcg/kg + 
psychotherapy + 
hypnosis 
No No significant difference between groups 2 'LSD sessions had to be terminated' Not reported 
Bogenschultz 
et al. 2015 Alcoholism 
10 Alcohol 
dependence None 
Psilocybin 300mcg/kg 
or 400mcg/kg Yes 
Significant effect on the 
percentage of heavy drinking 
days relative baseline 
Mild elevation of BP 
1 vomiting, 1 diarrhea, 1 insomnia 
1 dropped out after first 
treatment 
Osorio et al. 2015 Depression 6 Recurrent depressive disorder None 
Ayahuasca 2.2ml/kg 
containing 0.8mg/ml 
DMT & 0.21mg/ml 
harmine 
Yes 
Significant reductions in 
depressive symptoms at 1 
day, 1 week & 3 weeks. 
3 vomiting. Frequency not reported: 
irritability, decreased insight Not reported 
Carhart-
Harris et al. 
(b) 
2017 Depression 
20 Treatment resistant 
major depressive 
disorder 
None Psilocybin 10mg & 25mg Yes 
Significant effects on self-
rated mood, maximal at 5 
weeks. 
1 'patient became uncommunicative' 
during the drug effect (duration not stated) 
15 'transient anxiety lasting for minutes' 
5 'transient nausea' 
3 'transient paranoia' 
8 'headaches lasting no longer 
than 1-2 days' 
No 'flashbacks or persisting 
perceptual changes' 
5 'sought and successfully 
obtained psilocybin between 3 & 
6 months [after treatment]' 
Sanches et al. 2016 Depression 17 Recurrent depressive disorder None 
Ayahuasca 2.2ml/kg 
containing 0.8mg/ml 
DMT & 0.21mg/ml 
harmine 
Yes 
Significant reductions in 
depressive symptoms up to 3 
week study end point. 
47% vomiting Not reported 
Grob et al. 2011 
Life 
threatening 
disease 
12 Anxiety/adjustment 
disorder secondary to 
an advanced cancer 
diagnosis 
Subjects act 
as their own 
control 
(randomised 
Psilocybin 200mcg/kg 
& 
Niacin 250mg (control) 
No 
No significant difference 
between groups (positive 
trends observed) 
Mild elevation of HR and diastolic BP 'No adverse psychological 
reactions from the treatment' 
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crossover) 
Gasser et al. 2014 
Life 
threatening 
disease 
12 Anxiety disorder 
secondary to an 
advanced cancer 
diagnosis 
Unblinded 
crossover 
LSD 200mcg &  
LSD 20mcg (control) Yes 
Significant reductions in state 
(not trait) anxiety at 2 
months, sustained for 12 
months 
18 reports of adverse events in LSD group 
vs. 8 in active placebo group 
6 reports of mild adverse events 
persisting until the next day 
No 'lasting psychotic or 
perceptional disorders' 
Ross et al.  2016 
Life 
threatening 
disease 
29 Cancer related 
anxiety and depression 
Blinded 
crossover 
Psilocybin 300mcg/kg 
& Niacin 250mg 
(control) 
Yes 
Immediate, substantial and 
sustained clinical benefits 
(statistically significant). 
Variety of outcome 
measures. 
Statistically significant increases in BP/PR 
28% 'headaches/migraines' 
14% 'nausea' 
17% 'transient anxiety' 
7% 'transient psychotic-like symptoms' 
No 'participants abused or 
became addicted to psilocybin' 
No 'cases of prolonged psychosis 
or hallucinogen persisting 
perception disorder' 
No 'participants required 
psychiatric hospitalisation' 
Griffiths et 
al. 2016 
Life 
threatening 
disease 
51 Life threatening 
cancer with anxiety 
and depression 
Blinded 
crossover 
Psilocybin 22mg/70kg 
or 30mg/70kg & 
Psilocybin 1mg/70kg or 
3mg/70kg 
Yes 
Statistically significant 
superiority of high dose vs 
low dose psilocybin 
34% systolic BP > 160 mmHg (high dose) 
13% diastolic BP > 100 mmHg (high 
dose) 
15% 'nausea or vomiting' 
21% 'physical discomfort (of any type) 
(high dose) 
32% 'psychological discomfort (of any 
type) (high dose) 
26% 'anxiety' (high dose) 
1 'headache'  
1 'transient paranoid ideation' (high dose) 
No 'cases of hallucinogen 
persisting perception disorder or 
prolonged psychosis' 
2/11 'delayed moderate headache 
after this high dose session' 
Sandison et 
al 1954 Neurosis 
9 Obsessional 
21 Depression/Anxiety 
4 Conversion hysteria 
2 Other 
None LSD 25-400mcg over 2 
- 40 weekly sessions Yes 
4/9 Obsessional 
recovered/improved 
18/21 Depression/anxiety 
recovered/improved 
3/4 Conversion hysteria 
recovered/improved 
2/2 Other 
recovered/improved 
Not reported Not reported 
Sandison & 
Whitelaw 1957 Neurosis 
93 Predominantly 
neurotic 
(Includes 30 from 
1954 paper) 
None LSD 50-200mcg Yes 
21 ‘recovered’ 
20 ‘greatly improved’ 
20 ‘moderately improved’ 
32 ‘not improved’ 
Suicidal ideation, self harm, 'anxiety' 
'Repetition of the acute phase of 
the experience days or weeks 
after treatment' 
Chandler & 
Hartman 1960 Neurosis 
44 Psychoneurosis 
36 Personality 
disorder/trait 
disturbance 
22 Sociopathic 
disorder 
8 Miscellaneous/Other 
None LSD 50-150mcg Yes 
4 'Outstanding improvement' 
20 'Marked improvement' 
26 'Considerable 
improvement' 
23 'Some improvement' 
15 'Slight improvement' 
19 'Little or no change' 
3 'Slightly worse' 
0 'Definitely worse' 
Not reported 
1 suicide (previous history of 
attempts). 1 transient psychosis 
(1 day). 
Whitaker (b) 1964 Neurosis 
49 psychoneurosis 
27 personality disorder 
21 sexual disorder 
3 residual 
schizophrenia 
100 patients 
treated in 
previous 
years similar 
in terms of 
'diagnosis 
and duration 
of illness' 
LSD 100-250mcg given 
3.28 times on average. 
Total of 328 treatments 
given. 
Yes 
LSD/Control 
47/12 'successful 
18/30 'borderline' 
35/58 'failure' 
No statistical comparison 
performed 
Rescue medication given in 14/328 (4.3%) 
of treatments because of 'uncontrollable 
acting out or intolerable distress'. 
'Several refused further treatment because 
they found the experience too distressing' 
1/328 (0.3%) 'recurrence of the 
LSD effect on the following day' 
'In about 1/3 of cases there was 
transient increased distress 
between sessions' 
No instance of delayed psychosis 
No instance of drug seeking 
behaviour 
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Savage et al. 1967 Neurosis 
63 psychoneurotic 
2 schizophrenic 
reaction 
117 personality 
disturbance 
9 sexual deviation 
24 alcohol addiction 
27 other mostly 
adjustment reaction 
None 
LSD 200-300mcg + 
Mescaline 200-400mg 
'if necessary' on one 
occasion 
Yes 
46 'marked improvement' 
64 'substantial improvement' 
87 'some improvement' 
41 'no improvement' 
5 'worse' 
Not reported 
1 'manic attack…treated 
successfully with psychotherapy' 
1 'transient psychotic episode 5 
months after LSD triggered by an 
alcoholic bender' 
1 'claimed he had been harmed 
mentally' 
Moreno et al. 2006 OCD 9 Obsessive 
compulsive disorder None 
Psilocybin 25mcg/kg, 
100mcg/kg, 200mcg/kg 
& 300mcg/kg 
No 
Significant main effect of 
time on YBOCS scores. No 
significant effect of dose. 
1 transient hypertension (mild) 
2 dropped out after session 1 'due to 
discomfort with hospitalization' 
Not reported 
Busch & 
Johnson 1950 Psychosis 
20 Schizophrenia 
3 Mania 
4 Psychoneurosis 
1 Psychosomatic 
1 Paranoid state 
None 
LSD. Dose not stated. 
Probably between 20 
and 60 mcg 
No 
Nil objective results reported  
'Improvement' in 2 
psychoneurotic patients 
No improvement in 
schizophrenia patients 
In order of frequency (numbers not 
stated): 'Gastric distress', 'nausea & 
vomiting', 'muscle irritability', 'dizziness', 
'pupil dilation', 'hallucinatory flashes of 
light', 'chilliness', 'increase in pulse rate', 
'headache', 'flushing of the skin' 
Not reported 
Hoch et al. 1951 Psychosis 
17 Pseudoneurotic 
schizophrenia 
26 Undeteriorated 
schizophrenia 
16 Deteriorated 
schizophrenia 
None Mescaline 400-600mg LSD 10-100mcg No 
Nil objective results reported 
4 'mild' deterioration 
1 'marked' deteriorating 
1 'severe' deterioration 
'Catatonic withdrawls' in 
deteriorated schizophrenia 
group 
Frequency not stated. 'Increased anxiety', 
'hostility', 'paranoid manifestations', 'visual 
hallucinations', 'slurred speech', 
'chilliness', 'headache', 'trembling', 
'flushing', 'numbness', 'sense of heat', 
'hyperacusis', 'pupillary dilatations', 
'nausea & vomiting', 'reinforces 
schizophrenic symptomatology & 
magnifies it'. 
Not reported 
Liddell & 
Weil-
Malherbe 
1953 Psychosis 
3 Depression 
4 Paranoid 
schizophrenia 
9 Other forms of 
schizophrenia 
2 Anxiety hysteria 
3 Psychopathic states 
None 
25-60mcg LSD 
40-60mg d-
methylamphetamine 
No 
None objective 
Worsening of psychosis in 
those with schizophrenia 
'Mood swings' with 
'predominant euphoria' noted 
with LSD 
Frequency not stated. 'Flushing', 
exacerbation of schizophrenic symptoms, 
'mood swings', 'shivering', 'piloerection', 
'agitation', 'terror', 'worsening of 
depression', somatic complaints 
Not reported 
Pennes 1954 Psychosis 
20 Pseudoneurotic 
schizophrenia 
25 Undeteriorated 
schizophrenia 
10 Deteriorated 
schizophrenia 
None 
Mescaline unknown 
dose 
LSD 10-120mcg 
No 
'Normalisation' reactions in 
0% 
'Intensification' reactions in 
100% given mescaline and 
64% with LSD  
Frequency not stated. 'Anxiety & tension', 
'hostility', 'paranoid manifestations', 
'depression', 'hypochondriasis', 'phobias', 
'somatic delusions', 'silliness', 
'mannerisms', 'stereotypies', 'hysterical 
manifestaiotns', 'inferiority feelings', 
'catatonic withdrawals' 
Not reported 
Denber & 
Merlis 1955 Psychosis 25 Schizophrenia None Mescaline 500mg IV No 
1 'complete remission' 
3 'temporary remission' 
21 'psychosis reactivated or 
worsened' 
Frequency not stated. 'Nausea', 
'wretching', 'vomiting', 'sweating', 
'palpitations', 'chest & neck pains', 
'dyspnea', 'anxiety', 'restlessness', 'panic', 
'visual hallucinations', 'auditory 
hallcinations', 'paranoid delusions', 
'somatic delusions', 'acute catatonic 
withdrawal' 
Not reported 
Merlis 1957 Psychosis 24 Chronic 
schizophrenia None Mescaline 500-750mg No 
1 'sufficient improvement for 
discharge' 
7 'temporarily improved' 
16 'no change' 
7 'anxiety', 'increased activity', 
'intensification of hallucinations & 
delusional thinking' 
Not reported 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Johnson et al. 2014 Tobacco 
addiction 15 Tobacco addiction None 
Psilocybin 20mg/70kg 
or 30mg/kg Yes 
Significant reductions in self-
reported daily smoking from 
intake to 6-month follow-up 
10/42 (23.8%) sessions included strong or 
extreme feelings of 'fear, fear of insanity 
or feeling trapped' 
Mild increases in BP/HR 
8/10 participants reported 
transient, mild post psilocybin 
headache responsive to simple 
analgesia 
No increases in objective 
bothersome visual effects at 6 
months 
 
Table 1. Summary of included studies, sorted by diagnostic category and year of publication. Lists of adverse events includes salient negatives.   PR = pulse 
rate. BP = blood pressure
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Figure 1. The effect of Schedule I on psychedelic drug research. Number of PubMed publications in which a classical psychedelic drug is found in the title 
expressed as a proportion of all PubMed publications, by year, from 1950 to 2016. 
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Highlights 
 
• Psychedelics may be useful for treating resistant depression, anxiety & addictions 
• Pilot trials with psilocybin in depression show early evidence of safety & efficacy 
• The legal & regulatory hurdles to approval are formidable, but surmountable 
